Jaguar Health, Inc. (JAGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated July 1, 2026, reports on corporate actions completed by Jaguar Health, Inc. The filing details the finalization of a previously announced conversion of Series O Convertible Preferred Stock into Common Stock.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on capital structure changes.
Material Changes
- Preferred Stock Conversion: On June 25, 2026, all outstanding Series O Preferred Stock automatically converted into Common Stock.
- Conversion Ratio: The conversion rate was 3.209 shares of Common Stock for each share of Series O Preferred Stock.
- Share Count Impact: Immediately following the conversion, there were 4,857,211 shares of Common Stock issued and outstanding.
- Warrant Adjustments: Holders of Eligible Warrants are now entitled to receive up to 839,000 shares of Common Stock upon exercise. This total comprises 68,593 original Warrant Shares and 770,407 Conversion Shares.
- Historical Context: The filing references a special dividend of Series O Preferred Stock paid on March 4, 2026, and a 1-for-35 reverse stock split effective April 30, 2026, which adjusted share counts retroactively.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, or specific risk factors beyond the description of the completed corporate events.
Investor Verification Checklist
- Verify the post-conversion total share count of 4,857,211 shares of Common Stock.
- Confirm the updated warrant exercise entitlements totaling 839,000 shares.
- Review the impact of the 1-for-35 reverse stock split on historical financial data and per-share metrics.
- Check for any subsequent filings regarding the dilution effects of the new share issuance.